Short answer: MGMT promoter methylation testing tells you whether the MGMT DNA-repair gene is silenced in a glioblastoma. Patients with a methylated MGMT promoter benefit more from temozolomide, so the result guides treatment, especially in older patients. Most labs test with bisulfite-based methods such as methylation-specific PCR (MSP) or pyrosequencing. Newer bisulfite-free qPCR, such as EpiDirect® MGMT, measures methylation directly in untreated DNA in about two hours on a standard real-time PCR instrument.
Last updated: November 2026
Why MGMT methylation status matters
MGMT (O6-methylguanine-DNA methyltransferase) repairs the DNA damage that alkylating chemotherapy such as temozolomide causes. When the MGMT promoter is methylated, the gene is switched off, the tumour cannot repair that damage, and the chemotherapy works better.
- Prediction: MGMT promoter methylation is the best-established predictive biomarker for benefit from temozolomide in IDH-wildtype glioblastoma.
- Older patients: the result often decides between temozolomide alone and radiotherapy alone when combined treatment is not suitable.
- Clinical trials: many glioblastoma trials stratify or select patients by MGMT status.
- Guidelines: European (EANO) neuro-oncology guidelines recommend determining MGMT promoter methylation status in glioblastoma.
Because a “methylated” or “unmethylated” result changes treatment, the method needs to be reliable close to its cut-off, work on small FFPE biopsies, and fit the lab’s turnaround time.
MGMT testing methods compared
| Method | DNA treatment | Result | Equipment | Typical considerations |
|---|---|---|---|---|
| Methylation-specific PCR (MSP) | Bisulfite conversion | Qualitative (methylated / unmethylated) | PCR + gel or qPCR | Widely used and inexpensive; interpretation of weak bands can be subjective |
| Pyrosequencing | Bisulfite conversion | Quantitative, per CpG site | Pyrosequencer | Common reference method; cut-off varies between labs; dedicated platform |
| Methylation-specific digital PCR | Bisulfite conversion | Quantitative | Digital PCR system | Very sensitive; dPCR platform needed |
| Methylation arrays (e.g. MGMT-STP27) | Bisulfite conversion | Quantitative score | Array scanner | Often done alongside methylation-based tumour classification; batch-based, several days |
| MS-MLPA | Methylation-sensitive restriction enzyme | Semi-quantitative | Capillary electrophoresis | No bisulfite; multi-step workflow |
| Bisulfite-free qPCR (EpiDirect® MGMT) | None | Quantitative | Standard real-time PCR instrument | About 2 hours; 0.5–50 ng input; CE-IVD under the IVDR |
The problem with bisulfite conversion
Bisulfite treatment converts unmethylated cytosines so that methylated and unmethylated DNA can be told apart. It is also harsh: it fragments DNA and loses a large share of the input. That matters most for small or poorly preserved FFPE biopsies, and the extra conversion step adds hands-on time, cost and a source of variation between runs.
Bisulfite-free MGMT testing with EpiDirect®
EpiDirect® MGMT Methylation qPCR Assay measures MGMT promoter methylation directly in untreated genomic DNA. It is built on PentaBase’s INA® chemistry: an EpiPrimer™ binds and primes amplification of methylated DNA, while unmethylated DNA is not amplified. A reference reaction measures the total DNA, and the ratio gives the methylation level.
- No conversion step: purified DNA goes straight into qPCR.
- Fast: results in under 2 hours.
- Low input: 0.5–50 ng of DNA from FFPE or fresh-frozen brain tumour tissue.
- Sensitive: detects methylation levels down to 1.5%.
- Standard instruments: validated on CFX96 / CFX Opus 96 (Bio-Rad), QuantStudio™ 5 and BaseTyper™ 48.4.
- Target: CpG sites in the DMR2 region of MGMT exon 1, the region most labs already test.
- Regulatory: CE-IVD under the IVDR, with conformity assessment by Notified Body 2797.
What the evidence shows
Bendixen et al., Nature Communications, 2023. The study introducing the EpiDirect technology compared EpiDirect MGMT with two bisulfite-based methylation-specific PCR assays on 42 FFPE brain tumour samples and reported high sensitivity and specificity. Read the paper.
Németh et al., Neuro-Oncology Advances, 2026. An independent group in Giessen and Heidelberg tested 35 FFPE IDH-wildtype glioblastomas with EpiDirect and four established or emerging methods: pyrosequencing, MGMT-STP27 from EPIC arrays, MSP and methylation-specific digital PCR. EpiDirect agreed with each method in 88.6–94.3% of cases (Cohen’s κ 0.77–0.89), with no significant directional bias, and all five assays gave the same classification in 30 of 35 tumours. The authors conclude that the results support analytical non-inferiority, and note that larger prospective studies with outcome data are still needed and that most disagreements were close to the assay cut-offs. Read the paper.
Close-to-cut-off disagreement is not specific to EpiDirect: it is seen between every pair of MGMT methods, and published pyrosequencing cut-offs themselves differ between labs.
Switching from pyrosequencing
Qiagen has announced that the last PyroMark CE-IVD therascreen® assays will be placed on the market by 26 May 2026, and that the therascreen® MGMT Pyro® Kit will be discontinued by 28 February 2027 or until stocks last. Labs that rely on it for MGMT testing need a validated replacement.
A typical switch to EpiDirect MGMT looks like this:
- Run in parallel: test a set of previously characterised samples, including cases close to your current cut-off, on both methods.
- Confirm the cut-off: compare classifications and agree how to handle results in the grey zone, for example by repeating samples near the threshold.
- Verify under ISO 15189: document precision and agreement for your lab’s accreditation, and take part in external quality assessment.
- Keep your instrument: EpiDirect runs on standard real-time PCR systems, so no pyrosequencer or new platform is needed.
Contact us to plan a verification study, or ask for the IFU and performance data.
What does MGMT methylation testing cost?
The cost per patient sample depends on more than the kit price:
- Conversion: bisulfite-based methods need a conversion kit and an extra workflow step. EpiDirect does not.
- Equipment: pyrosequencing, digital PCR and arrays need dedicated platforms. EpiDirect runs on the qPCR instrument most labs already have.
- Hands-on time and turnaround: a 2-hour qPCR run is cheaper to staff than a multi-day workflow and makes in-house testing practical instead of send-out testing.
- Batch size: controls and standards are shared across the samples in a run, so larger batches lower the cost per patient.
- Repeat tests: a method that works with less DNA can mean fewer failed tests on small biopsies.
An EpiDirect® MGMT kit contains 48 reactions, including positive and negative controls and two MGMT methylation standards (3% and 10%) for the standard curve. Pricing depends on your region and volume. Request a quote or find your local distributor.
Frequently asked questions
What is MGMT promoter methylation?
It is the addition of methyl groups to the promoter region of the MGMT gene, which switches the gene off. Tumours with a methylated MGMT promoter cannot repair the DNA damage caused by temozolomide as well, so they respond better to it.
Which MGMT test is most accurate?
There is no single gold standard. Pyrosequencing, MSP, digital PCR, methylation arrays and bisulfite-free qPCR all agree for most tumours and disagree mainly for samples close to the cut-off. A quantitative method with a validated cut-off and a clear policy for borderline results matters more than the specific technology.
Can MGMT methylation be tested without bisulfite conversion?
Yes. EpiDirect® MGMT measures methylation directly in untreated DNA by qPCR, and MS-MLPA uses methylation-sensitive restriction enzymes instead of bisulfite.
How much DNA is needed?
EpiDirect® MGMT works with 0.5–50 ng of purified DNA from FFPE or fresh-frozen tumour tissue with at least 20% tumour cells. Bisulfite-based methods usually need more input because conversion degrades part of the DNA.
How long does an MGMT test take?
With EpiDirect® MGMT the qPCR run takes under 2 hours after DNA extraction. Bisulfite-based methods add a conversion step, and array-based testing is usually run in batches over several days.
What will replace the Qiagen therascreen MGMT Pyro kit?
Each lab chooses its own replacement. EpiDirect® MGMT is a CE-IVD, IVDR-certified alternative that targets CpG sites in the same part of MGMT exon 1 and runs on standard qPCR instruments, so it can be verified against existing pyrosequencing results without new equipment.
